We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology
News

MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology

MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology
News

MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDRNA Announces Worldwide Non-Exclusive Licensing Agreement for RNAi Delivery Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MDRNA will receive $7.25 million in upfront fees for the non-exclusive license. Additionally, the companies have entered into a separate agreement, which provides Novartis with an exclusive period to negotiate a research and development collaboration and broader licensing rights related to MDRNA's RNAi drug delivery platform. Terms of this separate agreement were not disclosed.


"We are pleased to enter into this agreement with Novartis, a global leader in the field of RNAi-based therapeutics," stated J. Michael French, President and Chief Executive Officer of MDRNA. "MDRNA's DiLA2 technology for siRNA delivery is effective and efficient at silencing gene targets in the liver and jejunum. Further, the in vivo tolerability of the DiLA2 technology is excellent. We have not observed any delivery related adverse effects in the liver as measured by typical serum chemistries or any significant increases in cytokine levels, which are hallmarks of cell damage. We view this license as yet another important validation of our siRNA technologies and we look forward to a strong and growing relationship with Novartis."

 

Advertisement